HARNESSING THE POWER OF PRECISION MEDICINE TO TREAT ALZHEIMER S DISEASE AND ALS (LOU GEHRIG S DISEASE)
|
|
- Roxanne Russell
- 6 years ago
- Views:
Transcription
1 HARNESSING THE POWER OF PRECISION MEDICINE TO TREAT ALZHEIMER S DISEASE AND ALS (LOU GEHRIG S DISEASE) Toronto Stock Exchange (TSX) ticker: PMN.TO June
2 Forward Looking Statement: Safe Harbor This slide deck may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this slide deck. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings available online at Actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 2
3 Investment Highlights ProMIS is developing a portfolio of personalized, best in class disease modifying therapies Monoclonal antibodies that target the root cause of Alzheimer s Disease (AD) AD has tremendous market value potential Greatest unmet need in medicine Expected to increase Decades of research disappointments have yielded new insights about AD s root cause Pointing a new direction to effective therapy Our platform technology patented processes can identify Disease Specific Epitopes Potential targets for additional antibody drugs and diagnostics ProMIS Neurosciences is publicly traded on the Toronto Stock Exchange (TSX) ticker: PMN.TO 3
4 The ProMIS Story has Two Main Components The Root Cause of Alzheimer s has become clear ProMIS is creating Best in Class therapies - The neuron killer is the Toxic Oligomer Form of beta-amyloid - Not beta amyloid plaque - This explains past failures and partial successes in clinical trials - Confirmed by a growing body of scientific evidence - ProMIS proprietary discovery technology has created products that selectively target the toxic oligomer, the root cause of AD - Biogen s aducanumab works, and will likely be first in class therapy - ProMIS is building a strong base of scientific evidence that PMN310, our lead program, is anticipated to be better than aducanumab 4
5 ProMIS is Developing REAL Solutions to an Immense Problem Acting faster than any competitor our proprietary technology platform has enabled us to capitalize on these new scientific insights about the root cause of AD Creating a portfolio of monoclonal antibody products with validated improvements anticipated over competitive products Our portfolio has the potential to change the standard of care in AD 5
6 AD Impacts Millions and Costs Billions The number of AD patients and associated costs are rising rapidly $500B Cost in the US, combining direct medical and indirect costs May bankrupt Medicare if the current trends are not reversed Fastest growing cause of death 1 Reviewed in Bloom 2014, JAMA Neurol Healthy Brain Brain with Mild Cognitive Impairment >15M Patients in US Brain with AD 1 >5M Patients in US 6
7 Amyloid beta (Aβ) Exists in Multiple Forms in the Brain The three forms of Aβ are monomer, oligomers, and plaque Monomer is created constantly in the brain as Amyloid Precursor Protein (APP) breaks down Monomer aggregates into oligomers, which then may further aggregate into fibrils and plaque Sometimes oligomers take on a toxic form = prions. Prions multiply rapidly (propagate) by causing new monomer (which is being created all the time) to take on the same toxic form nia.nih.gov 7 7
8 The Root Cause of AD: Toxic Oligomers of Aβ Toxic Aβ oligomers, also known as prions, are the real root cause of AD Aβ monomers and Aβ plaque have little or no demonstrable toxicity in vitro or in vivo 1-3 Soluble Aβ oligomers show the highest degree of neurotoxicity 4 Toxicity in primary neuron cultures and brain slices 1,3,5-7 Induction of cognitive impairment in rodents 3,4 Synaptotoxicity of human Ab oligomers on hippocampal neurons 5 Plaque is not the problem that explains many previous failures 1 Shankar et al, Nature Med 2008; 2 Cleary et al, Nature Neuroscience 2005; 3 Hong et al, Science 2016; 4 Benilova et al, Nature Neuroscience Review; 5 Lacor et al, J Neuroscience 2007; 6 Jin et al, PNAS 2011; 7 Lauren et al, Nature
9 Large Pharma Clinical Results Confirm; Selectively Target Toxic Oligomers Product Clinical Results Monomer binding BAD Plaque binding BAD Oligomer binding GOOD Companion Diagnostic GOOD Aducanumab (Biogen-fully human IgG1) Solanezumab (Eli Lilly-humanized IgG1) CTAD-2 yr. efficacy confirmed dose limiting # ARIA-E Likely 2021 Approval first in class CTAD-11% efficacy; p= rd failed phase 3 No Yes Yes No Yes No Yes No Verubecestat (Merck-BACE inhibitor) Pivotal failed (interim futility) Depletes Monomer N/A N/A No Bapineuzumab (Pfizer-humanized IgG1) Microhemorrhage, ARIA-E No cognitive benefit Yes Yes Yes No Efficacy Killer Creates Side Effects The target Critical for best efficacy # ARIA-E: Amyloid-Related Imaging Abnormality, or neurovascular edema 9
10 Dr. Eliezer Maslia, new head of US National Institute of Ageing, stressed the need for therapies that target the toxic oligomer at the AAN meeting in April 2017 A common mechanism underlies the top 3 neurodegenerative disorders, including Alzheimer s: Monomers aggregate into oligomers that are toxic to synapses and propagate in a prion-like fashion. Need to target oligomers of Ab, Tau, a-synuclein [with therapy] Biogen s aducanumab is showing promise, since it targets aggregated Amyloid beta [oligomers] 10
11 Target Product Profile for Best in Class Aβ mabs is Clear Products meeting these criteria are likely to have better clinical data than Aducanumab s expected label NO MONOMER BINDING NO PLAQUE BINDING HIGHLY SELECTIVE BINDING TO TOXIC OLIGOMER PERSONALIZED MEDICINE WITH COMPANION DIAGNOSTIC - Monomer outnumbers oligomers fold - Monomer binding reduces efficacy through target distraction - Target distraction reduces efficacy - Plaque may be protective sequester oligomers - Plaque binding contributes to ARIA-E - Targets root cause of neuronal death - Must be highly selective to avoid target distraction - Any single monoclonal antibody will have non-responders due to different toxic oligomer strains 11
12 ProMIS Best in Class Playbook; Building the Pharmasset of Alzheimer s The three largest products in industry history were not first in class, but best in class - Solvaldi/Harvoni, Humira, Lipitor They evaluated predecessor compounds and executed scientific strategies for creating meaningful improvements Pharmasett created Solvadi, best in class therapy in Hepatitis C, and sold to Gilead after Ph2 data for $11B ProMIS is creating the Pharmasett of Alzheimer s, with clear science-based improvements over likely first in class therapy Aducanumab from Biogen ProMIS competitive advantage lies in our platform technology, patented processes that allow us to identify Disease Specific Epitopes (targets for antibody drugs and diagnostics) 12
13 Toxic Oligomers Spread Through Brain - Killing Neurons & Causing AD Amyloid beta (Aβ) Propagation or spreading Neurotoxic oligomers kill neurons ~100B Neurons in a Healthy Brain Neurotoxic Oligomers form 13
14 ProMIS Antibodies Stop Toxic Oligomers Amyloid beta (Aβ) Propagation or spreading Neurotoxic oligomers kill neurons Neurotoxic Oligomers form ProMIS antibody products disable toxic oligomers and stop them from spreading 14
15 Administration of PMN310 to Mice Prevents Loss of Short-Term Memory Formation Caused by Toxic Oligomers AbO +/- Mab 7 days Novel Object Recognition Assay Control mice remember a familiar object when reexposed to it and spend more time exploring a new object Oligomer-injected mice lose the ability to discriminate between known and novel objects and spend equivalent amounts of time exploring both 0.6 Discrimination Index * * Vehicle # AβO PMN vehicle PMN AβO N=12 per arm *different from AβO (p < 0.05) # different from vehicle (p <0.05) Discrimination index = (Time exploring new object time exploring familiar object) / total exploration time Results press released January 9, 2017, 15
16 PMN310 Differentiation Plan PMN310 as Best in Class vs Aducanumab Property Aducanumab PMN310 Binding pattern Binds oligomers, plaque Binds toxic oligomers only Side effects - ARIA ARIA caused by plaque binding & IgG1 effector isotype ARIA not expected: no plaque binding & IgG4 non-effector isotype Therapeutic efficacy - Positive dose-dependent signal in Phase 2 - Therapeutic window limited by ARIA (dose limiting toxicity) No dose limiting toxicity expected -> Greater levels of CNS exposure and efficacy Response rate A priori non-responders cannot be prospectively identified Detection of target in CSF/blood (companion diagnostic) to allow for selection of likely responders ARIA: Amyloid-related imaging abnormalities 16
17 Compelling Best in Class Data Package Creation for PMN310 Product Feature Biogen s Aducanumab PMN310 existing data PMN310 Advantage Binding Profile Toxic Oligomer and plaque AAIC 2016 Toxic oligomer only AAIC 2016 ADPD 2017,AAN 2017 PMN310 more selective for the neuron killers ARIA-E, Brain swelling side effect 55% in highest dose arm, 35% with dose titration CTAD 2016 IgG4 isotype Little or no ARIA-E expected due to IgG4 and no plaque binding Dosing Dose titration that reduced ARIA-E also reduced efficacy CTAD 2016 PMN310 likely to be able to dose higher, increasing efficacy Personalized or Precision Medicine None PMN310 selectively targets a known epitope PMN310 companion diagnostic will eliminate non responders, increase efficacy AAIC, CTAD, and ADPD are leading international Alzheimer s Disease science meetings 17
18 ProMIS Best in Class Therapy - Significant Progress & Key Catalysts On track for 2017 Further in vivo efficacy data on lead product PMN310 Includes both behavioral and functional outcomes Further in vivo validation of other mabs Cohort Study to assess prevalence of different strains of toxic oligomers underlining need for precision medicine Development of companion diagnostics Development of blood based screening assay Tau and TDP43: Identification & IP filings on specific epitope targets 18
19 PMN310: Key Steps in Development Plan to Clinical Proof of Concept (POC) q q q q q q q q 2016 Create mabs 2016 Select best candidates, In Vitro Validation 2017 In Vivo Validation 2018 Manufacturing scale-up 2018 GLP animal toxicology Late 2018 IND Submission 2019 Phase 1 Single Ascending Dose Trial 2021 Phase 2 Proof of Concept Trial Complete 19
20 Numerous Prior AD Programs Targeting Aβ Help Set Expectations for Path Forward GLP Tox Manufacture Ph 1 SAD Ph 2 POC - Numerous previous programs have had success, few issues in GLP toxicolgy, manufacturing or bioavailability - High odds of success - ProMIS trial to be larger than Biogen s Aducanumab (n=166) - ProMIS to develop Companion Diagnostic (CDx) to ensure patients in trial have correct oligomer strain Expectations: better data than Aducanumab 1) no ARIA-E due to no plaque binding, IgG4 isotype 2) Higher efficacy higher dose possible 3) Higher efficacy CDx, no a priori non-responders Ph1 SAD = phase 1 trial, single ascending dose Ph2 POC = phase 2 trial, proof of concept 20
21 ProMIS Neurosciences: Summary Developing personalized, best in class therapies targeting the root cause of Alzheimer s disease Lead product PMN310 on track to: further confirm differentiation from likely first in class aducanumab in 2017 file IND late 2018, and generate better clinical data in 2021 shortly after aducanumab anticipated approval ProMIS proprietary technology platform is generating additional differentiated products in dementia and ALS Numerous catalysts near term Cohort study, personalized medicine Lead product PMN310 functional differentiation Other portfolio positive results ProMIS pursuing NASDAQ listing, likely in
22 ProMIS has very Experienced Management and Outstanding Advisory Boards Management Gene Williams, Executive Chairman - Genzyme, DART, Adheris Elliot Goldstein, CEO - Maxygen, DART, GSK Neil Cashman, Chief Science Officer - University of British Columbia Steven Plotkin, Chief Physics Officer - University of British Columbia Johanne Kaplan, Chief Development Officer - Genzyme, GSK Advisory Boards Todd Golde Scientific Adv. Bd. (SAB) - University of Florida William Mobley (SAB) - University of Cailfornia, San Diego Lary Walker (SAB) - Emory University Mara Aspinall Business Adv. Bd. (BAB) - Ventana, Genzyme Nigel Burns (BAB) - CAT, SweetSpot Michael Higgins (BAB) - Ironwood, Genzyme, Voyager 22 23
23 ProMIS has Successfully Raised $7.7MM CDN in Four Rounds, at Increasing Values, Since a Strategic Restart in July 2015 MKT CAP JUNE 2 $62MM $25MM Financial Status $10MM $2MM $2.5MM at $2MM Pre $1M M at $9M M Pre $1.5MM at $24MM Pre $2.7MM at $26MM Pre 201MM common shares outstanding ~240MM including options and warrants Current burn rate ~$300k due to efficient science process Restart July 2015 May 2016 Sep 2016 Feb 2017 Cash life into Q
24 Thank You We appreciate your interest in ProMIS Neurosciences and the exciting developments in AD therapeutics. Please feel free to contact us with any additional questions. Eugene Williams, Executive Chairman +1 (617) Elliot Goldstein, MD, CEO +1 (415) Website: Twitter: LinkedIn: 24
HARNESSING THE POWER OF PRECISION MEDICINE TO TREAT ALZHEIMER S AND OTHER NEURODEGENERATIVE DISEASES
HARNESSING THE POWER OF PRECISION MEDICINE TO TREAT ALZHEIMER S AND OTHER NEURODEGENERATIVE DISEASES Toronto Stock Exchange (TSX) ticker: PMN.TO U.S. OTC Pink Sheet ticker: ARFXF NOVEMBER 2017 1 Forward
More informationProMIS Neurosciences: therapies for neurodegenerative disease based on a proprietary discovery platform
ProMIS Neurosciences: therapies for neurodegenerative disease based on a proprietary discovery platform Toronto Stock Exchange (TSX) ticker: PMN.TO OTCQB ticker: ARFXF October 2018 1 Forward looking statement:
More informationADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT
FOR IMMEDIATE RELEASE December 21, 2017 Eisai Co., Ltd. Biogen Inc. ADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT CRITERIA FOR SUCCESS AT 12-MONTH ANALYSIS
More informationTARGETING ALZHEIMER S AND OTHER NEURODEGENERATIVE DISEASES WITH NOVEL THERAPEUTICS AND DIAGNOSTICS
TARGETING ALZHEIMER S AND OTHER NEURODEGENERATIVE DISEASES WITH NOVEL THERAPEUTICS AND DIAGNOSTICS NASDAQ: ACIU Credit Suisse Healthcare Conference Prof. Andrea Pfeifer Nov 7, 2017 2017 AC Immune. Not
More information12-Month Interim Analysis of APOE4 Carriers for Fixed and Titration Dosing Regimens in PRIME, a Phase 1b study of Aducanumab
12-Month Interim Analysis of APOE4 Carriers for Fixed and Titration Dosing Regimens in PRIME, a Phase 1b study of Aducanumab Vissia Viglietta, 1 John O Gorman, 1 Leslie Williams, 1 Tianle Chen, 1 Ahmed
More informationPriavoid. A life without dementia. Company Presentation, BIO, June, Prof. Dr. Dieter Willbold
Priavoid A life without dementia Company Presentation, BIO, June, 2017 Prof. Dr. Dieter Willbold (co-founder and future Chairman of the Supervisory Board) The Company At a glance Established: probably
More informationFrom Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager
From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,
More informationThe Importance of Early Identification of Alzheimer s Disease
The Importance of Early Identification of Alzheimer s Disease Alessandro Padovani Professor of Neurology, Director of the Institute of Neurology University of Brescia X No, nothing to disclose Yes, please
More informationBioArctic. Gunilla Osswald, PhD, CEO December 4, 2017 Lars Lannfelt, Professor, MD, Senior Advisor and Co-Founder
BioArctic Gunilla Osswald, PhD, CEO December 4, 2017 Lars Lannfelt, Professor, MD, Senior Advisor and Co-Founder Disclaimer This presentation has been prepared and produced by BioArctic AB (publ) ( BioArctic
More informationGenmab an antibody innovation powerhouse. Jan van de Winkel
Genmab an antibody innovation powerhouse Jan van de Winkel Forward Looking Statement This presentation contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationGunilla Osswald, PhD, CEO RedEye CNS Event, October 4, 2018
BioArctic AB Company presentation Gunilla Osswald, PhD, CEO RedEye CNS Event, October 4, 2018 Disclaimer This presentation has been prepared and produced by BioArctic AB (publ) ( BioArctic ) solely for
More informationORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 2018
ORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 2018 -$0.04/share for the 12 months ended December 31st MADRID, SPAIN and CAMBRIDGE, MA, February 15,
More informationAntibody against Chikungunya virus (mrna-1944)
Antibody against Chikungunya virus (mrna-1944) Modality Program # Program Indication Preclinical development Phase 1 Phase 2 Phase 3 and commercial Moderna rights mrna-1944 Antibody against Chikungunya
More informationCNS Gene Regulation Platform
CNS Gene Regulation Platform 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
More informationBioArctic AB Interim Report January - June Gunilla Osswald, CEO Jan Mattsson, CFO August 23, 2018
BioArctic AB Interim Report January - June 2018 Gunilla Osswald, CEO Jan Mattsson, CFO August 23, 2018 Disclaimer This presentation has been prepared and produced by BioArctic AB (publ) ( BioArctic ) solely
More informationOpexa Therapeutics, Inc.
Opexa Therapeutics, Inc. November 2011 Neil Warma President & CEO Forward-Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions
More informationuniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B -- Second-dose Cohort Demonstrates Dose Response with All Patients
More informationGrifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer s disease using its AMBAR treatment protocol
Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer s disease using its AMBAR treatment protocol Grifols presents AMBAR (Alzheimer Management by Albumin Replacement)
More informationBioArctic Gunilla Osswald, CEO December 5, Carnegie Nordic Healthcare Day
BioArctic Gunilla Osswald, CEO December 5, 2017 Carnegie Nordic Healthcare Day Disclaimer This presentation has been prepared and produced by BioArctic AB (publ) ( BioArctic ) solely for the benefit of
More informationQuarter Newsletter
Quarter 3 2016 Newsletter The Consortium continues to increase its membership reflecting the urgent need to develop new products for Alzheimer s disease. As of September 2016, there are over 60 people
More informationAD/PD Conference, Nice, Fr, 2015
AD/PD Conference, Nice, Fr, 2015 Overview, novelties and conclusions for domestic research NAP B MTA TTK MS Neuroproteomics Group Overlaping molecular mechanisms of miss-folded protein based neurodegenerative
More information2014 Annual and Special Meeting of Shareholders May 7, Roberto Bellini President and Chief Executive Officer
2014 Annual and Special Meeting of Shareholders May 7, 2014 Roberto Bellini President and Chief Executive Officer Twitter: @rbellini Key Strengths Late stage and diversified product portfolio Fully funded
More informationAffimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH
FOR IMMEDIATE RELEASE Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated;
More informationUniversity of California Center for Accelerated Innovation
University of California Center for Accelerated Innovation MICHAEL PALAZZOLO April 6, 2015 Outline CAI overview and introduction RFA and important dates Selection process Pre-application Finding help 2
More informationCapo Therapeutics, Inc.
Capo Therapeutics, Inc. Vaccine Therapies for Debilitating Diseases of the Brain San Diego, CA 1 SCIENTIFIC ADVISORY BOARD M. Flint Beal, M.D. Dr. Beal is an internationally recognized authority on neurodegenerative
More informationREDX PHARMA PLC ( Redx or Company or Group ) Interim Results
24 May 2016 AIM: REDX REDX PHARMA PLC ( Redx or Company or Group ) Interim Results Redx (AIM: REDX), the drug discovery and development company, is pleased to announce its unaudited interim results for
More informationNIH-RAID: A ROADMAP Program
NIH-RAID: A ROADMAP Program (Rapid Access to Interventional Development} A Program designed to facilitate the development of new therapeutics The NIH-RAID Pilot Program is intended to reduce some of the
More informationCompany Report Daring to be different
Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we
More informationLUPAS Luminescent Polymers for in vivo Imaging of Amyloid Signatures
LUPAS Luminescent Polymers for in vivo Imaging of Amyloid Signatures A research project for innovative diagnostics for neurodegenerative disorders Funded by the European Union under the 7 th Framework
More informationToxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development
Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA
More informationAntibody therapeutic approaches for cancer
Antibody therapeutic approaches for cancer Date2innovate Utrecht, March 21, 2014 Jan van de Winkel Forward Looking Statement This presentation contains forward looking statements. The words believe, expect,
More informationQPS Neuropharmacology Overview
HISTOCHEMISTRY HISTOLOGY KO MODELS IN VIVO MODELS BLOOD BRAIN BARRIER IN VITRO MODELS NEUROPHARMACOLOGY OVERVIEW NEUROSCIENCES QPS Neuropharmacology Overview QPS is recognized all over the world as a leading
More informationUnlocking protein production with translational read-through for rare genetic diseases. Investor Presentation February 2018
Unlocking protein production with translational read-through for rare genetic diseases Investor Presentation February 2018 1 Forward-Looking Statements Certain statements included in this presentation
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationSORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationCompound Re-Profiling. Dr Robert Scoffin CEO, Cresset
Compound Re-Profiling Dr Robert Scoffin CEO, Cresset What is it? F F F N N H 2 N S O O Br > Compound Re-Profiling or Re-Purposing is the process of finding a new clinical use for an existing treatment
More informationEARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles
EARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles BrainDTech team Dr. Fabio Bianco, PhD Chief Executive Officier PhD in Pharmacology, Degree in Biotech
More informationResults to be Presented at LDN WORLD Symposium in February Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13
Amicus Therapeutics Announces Positive Results from All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease Strong Proof-of-Concept Data for Chaperone
More informationHSCI: the first Russian public biotech company
HSCI: the first Russian public biotech company (expanding into new geographic markets) TEASER for Investor presentation (road-show for sale of 28.6 % of HSCI s increased share capital) June 2014 Disclaimer
More information2016 Summary Financial Results
ARCA BIOPHARMA ANNOUNCES FISCAL YEAR 2016 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE -------------------------------------------------------------------------------------------------- GENETIC-AF Phase
More informationGrifols has acquired 51% of the capital of Araclon Biotech to ensure the viability of the purchased company projects
Alzheimer s disease acquires a growing role in Grifols R&D Grifols has acquired 51% of the capital of Araclon Biotech to ensure the viability of the purchased company projects Araclon Biotech, established
More informationEngaging stakeholders for a holistic therapy in Alzheimer s disease
Engaging stakeholders for a holistic therapy in Alzheimer s disease Brain Forum l Lausanne, May 26, 2016 l Prof. Andrea Pfeifer 2016 AC Immune. Not to be used or reproduced without permission. www.acimmune.com
More informationPresentation to J.P. Morgan 33rd Annual Healthcare Conference. Moshe Manor President and CEO January 15, 2015
Presentation to J.P. Morgan 33rd Annual Healthcare Conference Moshe Manor President and CEO January 15, 2015 1 Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationJ.P. Morgan Healthcare Conference. January 15, 2009
J.P. Morgan Healthcare Conference January 15, 2009 Facet Biotech Corporation Forward-looking Statements This presentation contains forward-looking statements involving risks and uncertainties and Facet
More informationJefferies Healthcare Conference. June 2016
Jefferies Healthcare Conference June 2016 Forward Looking Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation
More informationFourth Quarter and Full Year Financial and Operational Results Conference Call March 21, 2018
Fourth Quarter and Full Year 2017 Financial and Operational Results Conference Call March 21, 2018 Copyright Akari Therapeutics, Plc - 2018 Disclaimers Certain statements in this presentation constitute
More informationCorporate Presentation July 9, Roberto Bellini President and Chief Executive Officer
Corporate Presentation July 9, 2018 r Roberto Bellini President and Chief Executive Officer Twitter: @rbellini Forward-Looking Statements Certain statements contained in this presentation, other than statements
More informationNuevolution AB (publ) Presentation Q4 2015/16
Nuevolution AB (publ) Presentation Q4 2015/16 FORWARD-LOOKING STATEMENTS Slide 2 Matters discussed in this presentation may constitute forward-looking statements. Forward-looking statements are statements
More informationAgios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. The people pictured here are some of the many friends and family of Agios employees affected by cancer. All of us at Agios are passionate about transforming patients lives.
More informationI. Company Information
Please fill out this form as completely as possible. Note: There is no fee to apply. Please send additional materials such as your pitch deck and executive summary to resi@lifesciencenation.com for us
More informationBioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
November 9, 2018 BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update NEW HAVEN, Conn., Nov. 09, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ( BTI ) (Nasdaq:
More informationElena BM Breidenstein, PhD 21 April 2018
Discovery of a Novel Oral Antibiotic, DDS-01 (SMT-571), to Treat Multi-Drug Resistant Neisseria gonorrhoeae Enabled by a Proprietary Transposon Technology Elena BM Breidenstein, PhD 21 April 2018 Forward-Looking
More informationform of testing is used and is
Universal Biosensors, Inc. ABN 51 121 559 993 1 Corporate Avenue Rowville Victoria 3178 Australia Telephone: +61 3 9213 9000 Facsimile: +61 3 9213 9099 Email: info@universalbiosensors.com www.universalbiosensors.com
More informationBioArctic AB Interim Report Jan Sep Jan Mattsson, CFO November 8, 2018
BioArctic AB Interim Report Jan Sep 2018 Gunilla Osswald, CEO Nasdaq Stockholm: BIOA B Jan Mattsson, CFO November 8, 2018 Disclaimer This presentation has been prepared and produced by BioArctic AB (publ)
More informationMarket Analysis & Segmentation. Gary Phillips CEO Bioshares 29 July 2016
Market Analysis & Segmentation Gary Phillips CEO Bioshares 29 July 2016 1 Forward looking statement This document contains forward looking statements, including statements concerning Pharmaxis future financial
More informationRobust and Durable Target Silencing in the CNS with sirna Conjugates
Robust and Durable Target Silencing in the CNS with sirna Conjugates Stuart Milstein October 2, 2018 1 2018 Alnylam Pharmaceuticals, Inc. Alnylam Forward Looking Statements This presentation contains forward-looking
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationINVESTOR PRESENTATION 2018
INVESTOR PRESENTATION 2018 IMMUNOPRECISE ANTIBODIES, LTD. UNIT 3204-4464 MARKHAM STREET VICTORIA, BRITISH COLUMBIA V8Z 7X8, CANADA IMMUNOPRECISE.COM 1 Disclosures DISCLAIMER This presentation is not, and
More informationLETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases Round 2
LETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases Round 2 DEADLINE: March 13, 2019, 2:00pm EDT Applicants will be notified of Proposal invitations in May 2019 This Letter of Intent
More informationLETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases Round 2
LETTER OF INTENT Rapid Response: Canada 2019 Parkinson s & Related Diseases Round 2 DEADLINE: May 15, 2019, 2:00pm EDT Applicants will be notified of Proposal invitations in August 2019 This Letter of
More informationMomenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation contains forward-looking statements about our financial outlook,
More informationI. Company Information
If your company won (1st-3rd place) an Innovation Challenge since RESI JPM 2018, or were a finalist at RESI NYC 2018, you do not qualify to participate in the Innovation Challenge at RESI JPM 2019. Please
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationWelcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications
Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More informationCorporate Overview. June 2017
Corporate Overview June 2017 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included
More informationAn alternative path to commercial imaging agent viability companion imaging diagnostics. Adrian Nunn
An alternative path to commercial imaging agent viability companion imaging diagnostics. Adrian Nunn Adrian.nunn@bru.bracco.com 1 The three generic proofs for any drug adapted for molecular imaging (MI)
More informations c i e n c e q u a l i t y i n n o v a t i o n
s c i e n c e q u a l i t y i n n o v a t i o n FORWARD LOOKING STATEMENTS This presentation may contain certain statements including, without limitation, the words may, plan, will, estimate, continue,
More informationADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
More informationMarch 13, Dear Shareholder:
15245 Shady Grove Road Suite 470 Rockville, MD 20850 301.208.9191 March 13, 2017 Dear Shareholder: We would like to take this time to report on the business activities and accomplishments of RegeneRx in
More informationCORPORATE PRESENTATION January 2019
CORPORATE PRESENTATION January 2019 1 DISCLAIMER This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ( Outlook Therapeutics or the Company ) based on management s current
More informationADVANCING A NOVEL TREATMENT FOR SEPTIC SHOCK INVESTOR UPDATE
ADVANCING A NOVEL TREATMENT FOR SEPTIC SHOCK INVESTOR UPDATE April 2017 1 Forward Looking Statements Certain statements contained in this presentation constitute forward-looking information within the
More informationInterim Report H Reporting period January June 2016
Interim Report H1 2016 Reporting period January June 2016 Halle (Saale), 30 August 2016 Konrad Glund CEO Hendrik Liebers CFO Inge Lues CDO Frank Weber CMO Important notice and disclaimer This Presentation
More informationSpectral Medical Inc.
Spectral Medical Inc. Targeted therapy for septic shock March 2019 Forward Looking Statements Certain statements contained in this presentation constitute forward-looking information within the meaning
More informationCorporate Presentation. June 2015
Corporate Presentation June 2015 Forward Looking Statement/Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions.
More informationAbGn-107, an ADC Targets Gastrointestinal Tumors
AbGn-107, an ADC Targets Gastrointestinal Tumors For a Healthier Life Presented by Ron Lin Feb. 22, 2016 All Rights reserved AbGenomics International Inc. 4966 El Camino Real, Suite 200, Los Altos, CA
More informationFirst Quarter 2018 Financial Results. May 8, 2018
First Quarter 2018 Financial Results May 8, 2018 Agenda Introduction Sarah Carmody, Senior Director of Investor Relations Corporate Update Craig Wheeler, President and Chief Executive Officer First Quarter
More informationEagle Pharmaceuticals NASDAQ: EGRX
Eagle Pharmaceuticals NASDAQ: EGRX Scott Tarriff, CEO David Riggs, CFO June 2015 Forward Looking Statements This presentation contains certain forward-looking information about Eagle Pharmaceuticals that
More informationCorporate Presentation OCTOBER 2018
Corporate Presentation OCTOBER 2018 This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated
More informationCapital Raising Presentation January 2017
Capital Raising Presentation January 2017 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available to it as at the
More informationTogether, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days
Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting Together, all nine participants
More informationI. Company Information
Please fill out this form as completely as possible. Note: There is no fee to apply. Please send additional materials such as your pitch deck and executive summary to resi@lifesciencenation.com for us
More informationDevelopment of differentiated immuno-oncology therapeutics by using multivalent Nanobodies
Nanobodies Innovative therapeutics Development of differentiated immuno-oncology therapeutics by using multivalent Nanobodies Immune Checkpoint Inhibitors Europe Sandra Li - 17 November 2016 Forward looking
More informationAllergan to Acquire Naurex
NEWS RELEASE CONTACTS: ALLERGAN: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 NAUREX: Canale Communications Pam Lord pam@canalecomm.com 619-849-6003 Naurex Inc. Ashish Khanna
More information10 November Evotec reports nine months results: Upside materialising
10 November 2011 Evotec reports nine months results: Upside materialising - DISCOVERY ALLIANCE BUSINESS REPORTS PROFITABLE GROWTH WITH REVENUES UP 54% AND A POSITIVE OPERATING RESULT OF 9.5 M - STRONG
More informationBioArctic, Q Gunilla Osswald, CEO Jan Mattsson, CFO
BioArctic, Q3 2017 Gunilla Osswald, CEO Jan Mattsson, CFO Disclaimer This presentation has been prepared and produced by BioArctic AB (publ) ( BioArctic ) solely for the benefit of investment analysis
More informationContact: Dr Brad Walsh Mobile: Suite 2, Ground Floor, 75 Talavera Rd Macquarie Park, NSW
Contact: Dr Brad Walsh Mobile: +61 413 231 296 Suite 2, Ground Floor, 75 Talavera Rd Macquarie Park, NSW 2113 www.glytherix.com Forward Looking Statements This presentation was prepared primarily for the
More informationStifel Nicolaus Healthcare Conference. September 2012
Stifel Nicolaus Healthcare Conference September 212 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of
More informationJP Morgan Healthcare Conference January 9, 2012
JP Morgan Healthcare Conference January 9, 2012 SAFE HARBOR Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which are subject to a number
More informationMicar Innovation. Drug Discovery Factory for novel drug molecules
Problem There are so many incurable diseases around the world that need adequate novel compounds for the treatment, like: - Chronic pain still a pandemic in the 21 st century and affecting 1.5bn people
More informationAURINIA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated March
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationDocket #: FDA-2018-D-3268
Subject: Comment on FDA Draft Guidance for Industry Titled Rare Diseases: Early Drug Development and the Role of Pre-Investigational New Drug Application Meetings Docket #: FDA-2018-D-3268 ARM is an international
More informationSYNTHETIC BIOLOGICS, INC.
SYNTHETIC BIOLOGICS, INC. FORM DEFA14A (Additional Proxy Soliciting Materials (definitive)) Filed 05/12/14 Address 155 GIBBS STREET SUITE 412 ROCKVILLE, MD 20850 Telephone (734) 332-7800 CIK 0000894158
More informationJefferies 2016 Healthcare Conference. June 7, 2016
Jefferies 2016 Healthcare Conference June 7, 2016 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management
More informationI. Company Information
Please fill out this form as completely as possible. Note: There is no fee to apply. Please send additional materials such as your pitch deck and executive summary to resi@lifesciencenation.com for us
More informationSynthetic Biologics Reports Year End 2012 Financial Results
April 16, 2013 Synthetic Biologics Reports Year End 2012 Financial Results -- Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets -- ROCKVILLE, Md.,
More information